Abeona Therapeutics Inc.
ABEO
Rank in Stocks
#18077
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical... Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
Share Price
$2.54
Last synced: 2026-11-09
Market Cap
$145.25M
Change (1 day)
-39.09%
Change (1 year)
-39.09%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Abeona Therapeutics Inc. (ABEO)
Category
Healthcare
EPS for Abeona Therapeutics Inc. (ABEO)
EPS as of June 2026 TTM: $-1.14
According to Abeona Therapeutics Inc.'s latest financial reports, its current EPS (TTM) is $-1.14. At the end of 2025 the company had an EPS of $1.34, an increase over its 2024 EPS of $-1.55.
EPS history for Abeona Therapeutics Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.14 | -185.07% |
| 2025 | $1.34 | -186.45% |
| 2024 | $-1.55 | -38.74% |
| 2023 | $-2.53 | -54.25% |
| 2022 | $-5.53 | -74.28% |
| 2021 | $-21.50 | -5.49% |
| 2020 | $-22.75 | -40.24% |
| 2019 | $-38.07 | 27.71% |
| 2018 | $-29.81 | 81.77% |
| 2017 | $-16.40 | 2.50% |
| 2016 | $-16.00 | 21.58% |
| 2015 | $-13.16 | -96.55% |
| 2014 | $-381.50 | -597.07% |
| 2013 | $76.75 | -111.81% |
| 2012 | $-650.00 | 136.36% |
| 2011 | $-275.00 | -63.33% |
| 2010 | $-750.00 | -63.19% |
| 2009 | $-2.04K | -60.82% |
| 2008 | $-5.20K | -59.69% |
| 2007 | $-12.90K | 183.07% |
| 2006 | $-4.56K | 594.03% |
| 2005 | $-656.62 | -84.46% |
| 2004 | $-4.23K | 29.50% |
| 2003 | $-3.26K | -27.13% |
| 2002 | $-4.48K | 52.80% |
| 2001 | $-2.93K | -4.67% |
| 2000 | $-3.07K | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,473.68% |
US
|
|
| $-7.07 | 520.18% |
US
|
|
| $-5.29 | 364.04% |
AU
|
|
| $12.88 | -1,229.83% |
BE
|
|
| $21.56 | -1,991.23% |
NL
|
Questions about Abeona Therapeutics Inc.'s earnings per share (EPS)
What is Abeona Therapeutics Inc.'s earnings per share (EPS)?
Abeona Therapeutics Inc.'s earnings per share (EPS) over the last twelve months is $-1.14, as of Jun 2026.
What was Abeona Therapeutics Inc.'s earnings per share (EPS) in 2025?
In 2025, Abeona Therapeutics Inc.'s earnings per share (EPS) was $1.34, compared with $-1.55 in 2024.
How has Abeona Therapeutics Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Abeona Therapeutics Inc.'s earnings per share (EPS) was highest in 2025 ($1.34) and lowest in 2020 ($-22.75).
How does Abeona Therapeutics Inc.'s earnings per share (EPS) compare with similar companies?
Abeona Therapeutics Inc.'s earnings per share (EPS) ($-1.14) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.